{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:03:35Z","timestamp":1777950215620,"version":"3.51.4"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Italian Ministry of University and Research (MUR) PNRR \u2018National Center for Gene Therapy and Drugs based on RNA Technology","award":["CN00000041 CN3 Spoke #5 \u2018Inflammatory and Infectious Diseases\u2019"],"award-info":[{"award-number":["CN00000041 CN3 Spoke #5 \u2018Inflammatory and Infectious Diseases\u2019"]}]},{"name":"Italian Ministry of Health 'Multidisciplinary and Interregional Hub for Research and Clinical Experimentation To Combat Pandemics and Antibiotic Resistance'","award":["T4-AN-07, PAN-HUB"],"award-info":[{"award-number":["T4-AN-07, PAN-HUB"]}]},{"name":"Italian Ministry of Health 'Multidisciplinary and Interregional Hub for Research and Clinical Experimentation To Combat Pandemics and Antibiotic Resistance'","award":["T4-AN-07, PAN-HUB"],"award-info":[{"award-number":["T4-AN-07, PAN-HUB"]}]},{"name":"Italian Ministry of Health 'Multidisciplinary and Interregional Hub for Research and Clinical Experimentation To Combat Pandemics and Antibiotic Resistance'","award":["T4-AN-07, PAN-HUB"],"award-info":[{"award-number":["T4-AN-07, PAN-HUB"]}]},{"name":"Italian Ministry of University and Research","award":["PNC 0000001 D3 4 Health"],"award-info":[{"award-number":["PNC 0000001 D3 4 Health"]}]},{"name":"Italian Ministry of University and Research","award":["PNC 0000001 D3 4 Health"],"award-info":[{"award-number":["PNC 0000001 D3 4 Health"]}]},{"name":"Italian Ministry of University and Research (MUR) PNRR \u2018National Center for Gene Therapy and Drugs based on RNA Technology\u2019","award":["CN00000041 CN3 Spoke #5 \u2018Inflammatory and Infectious Diseases\u2019"],"award-info":[{"award-number":["CN00000041 CN3 Spoke #5 \u2018Inflammatory and Infectious Diseases\u2019"]}]},{"name":"Italian Ministry of University and Research (MUR) PNRR \u2018National Center for Gene Therapy and Drugs based on RNA Technology\u2019","award":["CN00000041 CN3 Spoke #5 \u2018Inflammatory and Infectious Diseases\u2019"],"award-info":[{"award-number":["CN00000041 CN3 Spoke #5 \u2018Inflammatory and Infectious Diseases\u2019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04637-0","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:34:37Z","timestamp":1777876477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From disease heterogeneity to precision therapy in type 1 diabetes mellitus"],"prefix":"10.1007","volume":"91","author":[{"given":"Laura","family":"Nigi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Dotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"Supplement1","key":"4637_CR1","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc26-S002","volume":"49","author":"M Bajaj","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*, M. Bajaj, R.G. McCoy, K. Balapattabi, R.R. Bannuru, N.J. Bellini et al., 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142026. Diabetes Care. 49(Supplement1), S27\u201349 (2026). https:\/\/doi.org\/10.2337\/dc26-S002","journal-title":"Diabetes Care"},{"issue":"4","key":"4637_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/genes13040706","volume":"13","author":"A Zajec","year":"2022","unstructured":"A. Zajec, K. Trebu\u0161ak Podkraj\u0161ek, T. Tesovnik, R. \u0160ket, B. \u010cugalj Kern, B. Jenko Bizjan et al., Pathogenesis of Type 1 Diabetes: Established Facts and New Insights. Genes. 13(4), 706 (2022). https:\/\/doi.org\/10.3390\/genes13040706","journal-title":"Genes"},{"issue":"S6","key":"4637_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/dom.16628","volume":"27","author":"KI Aamodt","year":"2025","unstructured":"K.I. Aamodt, A.C. Powers, The pathophysiology, presentation and classification of Type 1 diabetes. Diabetes Obes. Metabolism. 27(S6), 15\u201327 (2025). https:\/\/doi.org\/10.1111\/dom.16628","journal-title":"Diabetes Obes. Metabolism"},{"issue":"26","key":"4637_CR4","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1056\/NEJMc0805398","volume":"359","author":"MJ Redondo","year":"2008","unstructured":"M.J. Redondo, J. Jeffrey, P.R. Fain, G.S. Eisenbarth, T. Orban, Concordance for Islet Autoimmunity among Monozygotic Twins. N Engl. J. Med. 359(26), 2849\u20132850 (2008). https:\/\/doi.org\/10.1056\/NEJMc0805398","journal-title":"N Engl. J. Med."},{"issue":"10035","key":"4637_CR5","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/S0140-6736(16)30582-7","volume":"387","author":"F Pociot","year":"2016","unstructured":"F. Pociot, \u00c5. Lernmark, Genetic risk factors for type 1 diabetes. Lancet. 387(10035), 2331\u20132339 (2016). https:\/\/doi.org\/10.1016\/S0140-6736(16)30582-7","journal-title":"Lancet"},{"issue":"2","key":"4637_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2337\/db16-0806","volume":"66","author":"JS Skyler","year":"2017","unstructured":"J.S. Skyler, G.L. Bakris, E. Bonifacio, T. Darsow, R.H. Eckel, L. Groop et al., Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 66(2), 241\u2013255 (2017). https:\/\/doi.org\/10.2337\/db16-0806","journal-title":"Diabetes"},{"issue":"10035","key":"4637_CR7","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/S0140-6736(16)30507-4","volume":"387","author":"M Rewers","year":"2016","unstructured":"M. Rewers, J. Ludvigsson, Environmental risk factors for type 1 diabetes. Lancet. 387(10035), 2340\u20132348 (2016). https:\/\/doi.org\/10.1016\/S0140-6736(16)30507-4","journal-title":"Lancet"},{"issue":"7","key":"4637_CR8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00125-023-05927-2","volume":"66","author":"AG Ziegler","year":"2023","unstructured":"A.G. Ziegler, The countdown to type 1 diabetes: when, how and why does the clock start? Diabetologia. 66(7), 1169\u20131178 (2023). https:\/\/doi.org\/10.1007\/s00125-023-05927-2","journal-title":"Diabetologia"},{"issue":"7","key":"4637_CR9","doi-asserted-by":"publisher","first-page":"e70091","DOI":"10.1002\/dmrr.70091","volume":"41","author":"AW Michels","year":"2025","unstructured":"A.W. Michels, P.A. Gottlieb, B. Nelson, C. Dayan, Autoimmune Type 1 Diabetes in the Era of Disease-Modifying Immune Therapy. Diabetes Metabolism Res. 41(7), e70091 (2025). https:\/\/doi.org\/10.1002\/dmrr.70091","journal-title":"Diabetes Metabolism Res."},{"key":"4637_CR10","doi-asserted-by":"publisher","first-page":"1326711","DOI":"10.3389\/fimmu.2023.1326711","volume":"14","author":"JRN Lemos","year":"2024","unstructured":"J.R.N. Lemos, K. Hirani, Von M. Herrath, Immunological and virological triggers of type 1 diabetes: insights and implications. Front. Immunol. 14, 1326711 (2024). https:\/\/doi.org\/10.3389\/fimmu.2023.1326711","journal-title":"Front. Immunol."},{"issue":"9","key":"4637_CR11","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00125-025-06462-y","volume":"68","author":"C Evans-Molina","year":"2025","unstructured":"C. Evans-Molina, Y. Dor, \u00c5. Lernmark, C. Mathieu, J.R. Millman, R.G. Mirmira et al., The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment\u20142024 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia. 68(9), 1859\u20131878 (2025). https:\/\/doi.org\/10.1007\/s00125-025-06462-y","journal-title":"Diabetologia"},{"issue":"5","key":"4637_CR12","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00125-021-05398-3","volume":"64","author":"BJ Von Scholten","year":"2021","unstructured":"Von B.J. Scholten, F.F. Kreiner, S.C.L. Gough, Von M. Herrath, Current and future therapies for type 1 diabetes. Diabetologia. 64(5), 1037\u20131048 (2021). https:\/\/doi.org\/10.1007\/s00125-021-05398-3","journal-title":"Diabetologia"},{"issue":"2","key":"4637_CR13","doi-asserted-by":"publisher","first-page":"100044","DOI":"10.1016\/j.pharmr.2025.100044","volume":"77","author":"L Kosheleva","year":"2025","unstructured":"L. Kosheleva, D. Koshelev, F.A. Lagunas-Rangel, S. Levit, A. Rabinovitch, H.B. Schi\u00f6th, Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments. Pharmacol. Rev. 77(2), 100044 (2025). https:\/\/doi.org\/10.1016\/j.pharmr.2025.100044","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"4637_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S2213-8587(24)00239-0","volume":"12","author":"LM Jacobsen","year":"2024","unstructured":"L.M. Jacobsen, M.A. Atkinson, J.M. Sosenko, S.E. Gitelman, Time to reframe the disease staging system for type 1 diabetes. Lancet Diabetes Endocrinol. 12(12), 924\u2013933 (2024). https:\/\/doi.org\/10.1016\/S2213-8587(24)00239-0","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4637_CR15","doi-asserted-by":"publisher","first-page":"1477101","DOI":"10.3389\/fendo.2024.1477101","volume":"15","author":"AJ O\u2019Donovan","year":"2024","unstructured":"A.J. O\u2019Donovan, S. Gorelik, L.M. Nally, Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies. Front. Endocrinol. 15, 1477101 (2024). https:\/\/doi.org\/10.3389\/fendo.2024.1477101","journal-title":"Front. Endocrinol."},{"issue":"10","key":"4637_CR16","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"R.A. Insel, J.L. Dunne, M.A. Atkinson, J.L. Chiang, D. Dabelea, P.A. Gottlieb et al., Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 38(10), 1964\u20131974 (2015). https:\/\/doi.org\/10.2337\/dc15-1419","journal-title":"Diabetes Care"},{"issue":"9","key":"4637_CR17","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1210\/clinem\/dgaf267","volume":"110","author":"AW Michels","year":"2025","unstructured":"A.W. Michels, T.M. Brusko, C. Evans-Molina, D. Homann, S.J. Richardson, A.C. Powers, Challenges and Opportunities for Understanding the Pathogenesis of Type 1 Diabetes: An Endocrine Society Scientific Statement. J. Clin. Endocrinol. Metabolism. 110(9), 2496\u20132508 (2025). https:\/\/doi.org\/10.1210\/clinem\/dgaf267","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"4","key":"4637_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s00125-024-06356-5","volume":"68","author":"J Collins","year":"2025","unstructured":"J. Collins, N.L. Farnsworth, Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers. Diabetologia. 68(4), 692\u2013703 (2025). https:\/\/doi.org\/10.1007\/s00125-024-06356-5","journal-title":"Diabetologia"},{"issue":"3","key":"4637_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ecl.2010.05.011","volume":"39","author":"DM Maahs","year":"2010","unstructured":"D.M. Maahs, N.A. West, J.M. Lawrence, E.J. Mayer-Davis, Epidemiology of Type 1 Diabetes. Endocrinol. Metab. Clin. North Am. 39(3), 481\u2013497 (2010). https:\/\/doi.org\/10.1016\/j.ecl.2010.05.011","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"S6","key":"4637_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.16501","volume":"27","author":"KJ Bell","year":"2025","unstructured":"K.J. Bell, S.J. Lain, The Changing Epidemiology of Type 1 Diabetes: A Global Perspective. Diabetes Obes. Metabolism. 27(S6), 3\u201314 (2025). https:\/\/doi.org\/10.1111\/dom.16501","journal-title":"Diabetes Obes. Metabolism"},{"issue":"2","key":"4637_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.34172\/hpp.2020.18","volume":"10","author":"M Mobasseri","year":"2020","unstructured":"M. Mobasseri, M. Shirmohammadi, T. Amiri, N. Vahed, H. Hosseini Fard, M. Ghojazadeh, Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 10(2), 98\u2013115 (2020). https:\/\/doi.org\/10.34172\/hpp.2020.18","journal-title":"Health Promot Perspect."},{"issue":"8","key":"4637_CR22","doi-asserted-by":"publisher","first-page":"e030521193110","DOI":"10.2174\/1573399817666210503133747","volume":"17","author":"AG Abela","year":"2021","unstructured":"A.G. Abela, S. Fava, Why is the Incidence of Type 1. Diabetes Increasing? CDR. 17(8), e030521193110 (2021). https:\/\/doi.org\/10.2174\/1573399817666210503133747","journal-title":"Diabetes Increasing? CDR"},{"issue":"1","key":"4637_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12967-021-02778-6","volume":"19","author":"AAS Akil","year":"2021","unstructured":"A.A.S. Akil, E. Yassin, A. Al-Maraghi, E. Aliyev, K. Al-Malki, K.A. Fakhro, Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J. Transl Med. 19(1), 137 (2021). https:\/\/doi.org\/10.1186\/s12967-021-02778-6","journal-title":"J. Transl Med."},{"issue":"3","key":"4637_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00125-018-4763-3","volume":"62","author":"CC Patterson","year":"2019","unstructured":"C.C. Patterson, V. Harjutsalo, J. Rosenbauer, A. Neu, O. Cinek, T. Skrivarhaug et al., Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989\u20132013: a multicentre prospective registration study. Diabetologia. 62(3), 408\u2013417 (2019). https:\/\/doi.org\/10.1007\/s00125-018-4763-3","journal-title":"Diabetologia"},{"issue":"3","key":"4637_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S2213-8587(19)30412-7","volume":"8","author":"JM Norris","year":"2020","unstructured":"J.M. Norris, R.K. Johnson, L.C. Stene, Type 1 diabetes\u2014early life origins and changing epidemiology. Lancet Diabetes Endocrinol. 8(3), 226\u2013238 (2020). https:\/\/doi.org\/10.1016\/S2213-8587(19)30412-7","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"4637_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s43856-023-00357-y","volume":"3","author":"JL Felton","year":"2023","unstructured":"J.L. Felton, K.J. Griffin, R.A. Oram, C. Speake, S.A. Long, S. Onengut-Gumuscu et al., Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review. Commun. Med. 3(1), 130 (2023). https:\/\/doi.org\/10.1038\/s43856-023-00357-y","journal-title":"Commun. Med."},{"issue":"11","key":"4637_CR27","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3390\/cells12111472","volume":"12","author":"N Ajmal","year":"2023","unstructured":"N. Ajmal, M.C. Bogart, P. Khan, I.M. Max-Harry, C.S. Nunemaker, Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes. Cells. 12(11), 1472 (2023). https:\/\/doi.org\/10.3390\/cells12111472","journal-title":"Cells"},{"issue":"10511","key":"4637_CR28","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/S0140-6736(25)01438-2","volume":"406","author":"AG Ziegler","year":"2025","unstructured":"A.G. Ziegler, E. Cengiz, T.W.H. Kay, The future of type 1 diabetes therapy. Lancet. 406(10511), 1520\u20131534 (2025). https:\/\/doi.org\/10.1016\/S0140-6736(25)01438-2","journal-title":"Lancet"},{"issue":"1","key":"4637_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/bmb\/ldab027","volume":"140","author":"LA Allen","year":"2021","unstructured":"L.A. Allen, C.M. Dayan, Immunotherapy for type 1 diabetes. Br. Med. Bull. 140(1), 76\u201390 (2021). https:\/\/doi.org\/10.1093\/bmb\/ldab027","journal-title":"Br. Med. Bull."},{"issue":"5","key":"4637_CR30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1159\/000539120","volume":"98","author":"J Weiskorn","year":"2024","unstructured":"J. Weiskorn, T. Danne, Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes. Horm. Res. Paediatr. 98(5), 558\u2013565 (2024). https:\/\/doi.org\/10.1159\/000539120","journal-title":"Horm. Res. Paediatr."},{"issue":"10146","key":"4637_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","volume":"392","author":"A Rawshani","year":"2018","unstructured":"A. Rawshani, N. Sattar, S. Franz\u00e9n, A. Rawshani, A.T. Hattersley, A.M. Svensson et al., Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 392(10146), 477\u2013486 (2018). https:\/\/doi.org\/10.1016\/S0140-6736(18)31506-X","journal-title":"Lancet"},{"key":"4637_CR32","doi-asserted-by":"publisher","first-page":"101565","DOI":"10.1016\/j.molmet.2022.101565","volume":"64","author":"MG Scherm","year":"2022","unstructured":"M.G. Scherm, R.C. Wyatt, I. Serr, D. Anz, S.J. Richardson, C. Daniel, Beta cell and immune cell interactions in autoimmune type 1 diabetes: How they meet and talk to each other. Mol. Metabolism. 64, 101565 (2022). https:\/\/doi.org\/10.1016\/j.molmet.2022.101565","journal-title":"Mol. Metabolism"},{"issue":"4","key":"4637_CR33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/jpm12040542","volume":"12","author":"C Deligne","year":"2022","unstructured":"C. Deligne, S. You, R. Mallone, Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How? JPM. 12(4), 542 (2022). https:\/\/doi.org\/10.3390\/jpm12040542","journal-title":"JPM"},{"issue":"10","key":"4637_CR34","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1007\/s00125-025-06512-5","volume":"68","author":"LC Stene","year":"2025","unstructured":"L.C. Stene, Perspectives on prevention of type 1 diabetes and heterogeneities. Diabetologia. 68(10), 2104\u20132115 (2025). https:\/\/doi.org\/10.1007\/s00125-025-06512-5","journal-title":"Diabetologia"},{"issue":"11","key":"4637_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","volume":"15","author":"J Ilonen","year":"2019","unstructured":"J. Ilonen, J. Lempainen, R. Veijola, The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat. Rev. Endocrinol. 15(11), 635\u2013650 (2019). https:\/\/doi.org\/10.1038\/s41574-019-0254-y","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10","key":"4637_CR36","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1007\/s00125-020-05211-7","volume":"63","author":"MJ Redondo","year":"2020","unstructured":"M.J. Redondo, W.A. Hagopian, R. Oram, A.K. Steck, K. Vehik, M. Weedon et al., The clinical consequences of heterogeneity within and between different diabetes types. Diabetologia. 63(10), 2040\u20132048 (2020). https:\/\/doi.org\/10.1007\/s00125-020-05211-7","journal-title":"Diabetologia"},{"issue":"9","key":"4637_CR37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41574-023-00853-0","volume":"19","author":"MJ Redondo","year":"2023","unstructured":"M.J. Redondo, N.G. Morgan, Heterogeneity and endotypes in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 19(9), 542\u2013554 (2023). https:\/\/doi.org\/10.1038\/s41574-023-00853-0","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"4637_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/dc19-0880","volume":"43","author":"M Battaglia","year":"2020","unstructured":"M. Battaglia, S. Ahmed, M.S. Anderson, M.A. Atkinson, D. Becker, P.J. Bingley et al., Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care. 43(1), 5\u201312 (2020). https:\/\/doi.org\/10.2337\/dc19-0880","journal-title":"Diabetes Care"},{"issue":"1","key":"4637_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1084\/jem.20111187","volume":"209","author":"KT Coppieters","year":"2012","unstructured":"K.T. Coppieters, F. Dotta, N. Amirian, P.D. Campbell, T.W.H. Kay, M.A. Atkinson et al., Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 209(1), 51\u201360 (2012). https:\/\/doi.org\/10.1084\/jem.20111187","journal-title":"J. Exp. Med."},{"issue":"3","key":"4637_CR40","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00125-003-1089-5","volume":"46","author":"BO Roep","year":"2003","unstructured":"B.O. Roep, The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure. Diabetologia. 46(3), 305\u2013321 (2003). https:\/\/doi.org\/10.1007\/s00125-003-1089-5","journal-title":"Diabetologia"},{"issue":"4","key":"4637_CR41","doi-asserted-by":"publisher","first-page":"e3264","DOI":"10.1002\/dmrr.3264","volume":"36","author":"L Nigi","year":"2020","unstructured":"L. Nigi, C. Maccora, F. Dotta, G. Sebastiani, From immunohistological to anatomical alterations of human pancreas in type 1 diabetes: New concepts on the stage. Diabetes Metabolism Res. 36(4), e3264 (2020). https:\/\/doi.org\/10.1002\/dmrr.3264","journal-title":"Diabetes Metabolism Res."},{"issue":"7","key":"4637_CR42","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nri2787","volume":"10","author":"A Lehuen","year":"2010","unstructured":"A. Lehuen, J. Diana, P. Zaccone, A. Cooke, Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol. 10(7), 501\u2013513 (2010). https:\/\/doi.org\/10.1038\/nri2787","journal-title":"Nat. Rev. Immunol."},{"key":"4637_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/4106518","volume":"2020","author":"L Sun","year":"2020","unstructured":"L. Sun, S. Xi, G. He, Z. Li, X. Gang, C. Sun et al., Two to Tango: Dialogue between Adaptive and Innate Immunity in Type 1 Diabetes. J. Diabetes Res. 2020, 1\u20139 (2020). https:\/\/doi.org\/10.1155\/2020\/4106518","journal-title":"J. Diabetes Res."},{"issue":"1","key":"4637_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00281-010-0206-z","volume":"33","author":"FA Grieco","year":"2011","unstructured":"F.A. Grieco, F. Vendrame, I. Spagnuolo, F. Dotta, Innate immunity and the pathogenesis of type 1 diabetes. Semin Immunopathol. 33(1), 57\u201366 (2011). https:\/\/doi.org\/10.1007\/s00281-010-0206-z","journal-title":"Semin Immunopathol."},{"key":"4637_CR45","doi-asserted-by":"publisher","first-page":"606332","DOI":"10.3389\/fendo.2020.606332","volume":"11","author":"A Citro","year":"2021","unstructured":"A. Citro, F. Campo, E. Dugnani, L. Piemonti, Innate Immunity Mediated Inflammation and Beta Cell Function: Neighbors or Enemies? Front. Endocrinol. 11, 606332 (2021). https:\/\/doi.org\/10.3389\/fendo.2020.606332","journal-title":"Front. Endocrinol."},{"issue":"20","key":"4637_CR46","doi-asserted-by":"publisher","first-page":"eaao4013","DOI":"10.1126\/sciimmunol.aao4013","volume":"3","author":"S Culina","year":"2018","unstructured":"S. Culina, A.I. Lalanne, G. Afonso, K. Cerosaletti, S. Pinto, G. Sebastiani et al., Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci. Immunol. 3(20), eaao4013 (2018). https:\/\/doi.org\/10.1126\/sciimmunol.aao4013","journal-title":"Sci. Immunol."},{"issue":"6554","key":"4637_CR47","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1126\/science.abh1654","volume":"373","author":"JA Bluestone","year":"2021","unstructured":"J.A. Bluestone, J.H. Buckner, K.C. Herold, Immunotherapy, Building a bridge to a cure for type 1 diabetes. Science. 373(6554), 510\u2013516 (2021). https:\/\/doi.org\/10.1126\/science.abh1654","journal-title":"Science"},{"issue":"4","key":"4637_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrendo.2009.21","volume":"5","author":"DL Eizirik","year":"2009","unstructured":"D.L. Eizirik, M.L. Colli, F. Ortis, The role of inflammation in insulitis and \u03b2-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 5(4), 219\u2013226 (2009). https:\/\/doi.org\/10.1038\/nrendo.2009.21","journal-title":"Nat. Rev. Endocrinol."},{"issue":"8","key":"4637_CR49","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1369\/0022155415576543","volume":"63","author":"T Rodriguez-Calvo","year":"2015","unstructured":"T. Rodriguez-Calvo, J.S. Suwandi, N. Amirian, J. Zapardiel-Gonzalo, F. Anquetil, S. Sabouri et al., Heterogeneity and Lobularity of Pancreatic Pathology in Type 1 Diabetes during the Prediabetic Phase. J. Histochem. Cytochem. 63(8), 626\u2013636 (2015). https:\/\/doi.org\/10.1369\/0022155415576543","journal-title":"J. Histochem. Cytochem."},{"issue":"11","key":"4637_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11892-018-1084-3","volume":"18","author":"T Rodriguez-Calvo","year":"2018","unstructured":"T. Rodriguez-Calvo, S.J. Richardson, A. Pugliese, Pancreas Pathology During the Natural History of Type 1 Diabetes. Curr. Diab Rep. 18(11), 124 (2018). https:\/\/doi.org\/10.1007\/s11892-018-1084-3","journal-title":"Curr. Diab Rep."},{"issue":"3","key":"4637_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2337\/db15-0779","volume":"65","author":"M Campbell-Thompson","year":"2016","unstructured":"M. Campbell-Thompson, A. Fu, J.S. Kaddis, C. Wasserfall, D.A. Schatz, A. Pugliese et al., Insulitis and \u03b2-Cell Mass in the Natural History of Type 1 Diabetes. Diabetes. 65(3), 719\u2013731 (2016). https:\/\/doi.org\/10.2337\/db15-0779","journal-title":"Diabetes"},{"issue":"2","key":"4637_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2249.2008.03860.x","volume":"155","author":"A Willcox","year":"2009","unstructured":"A. Willcox, S.J. Richardson, A.J. Bone, A.K. Foulis, N.G. Morgan, Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155(2), 173\u2013181 (2009). https:\/\/doi.org\/10.1111\/j.1365-2249.2008.03860.x","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"4637_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4161\/isl.3.4.15728","volume":"3","author":"P In\u2019t Veld","year":"2011","unstructured":"P. In\u2019t Veld, Insulitis in human type 1 diabetes: The quest for an elusive lesion. Islets. 3(4), 131\u2013138 (2011). https:\/\/doi.org\/10.4161\/isl.3.4.15728","journal-title":"Islets"},{"issue":"3","key":"4637_CR54","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cmet.2018.11.014","volume":"29","author":"N Damond","year":"2019","unstructured":"N. Damond, S. Engler, V.R.T. Zanotelli, D. Schapiro, C.H. Wasserfall, I. Kusmartseva et al., A Map of Human Type 1 Diabetes Progression by Imaging Mass Cytometry. Cell Metabol. 29(3), 755\u2013768e5 (2019). https:\/\/doi.org\/10.1016\/j.cmet.2018.11.014","journal-title":"Cell Metabol."},{"issue":"18","key":"4637_CR55","doi-asserted-by":"publisher","first-page":"e122146","DOI":"10.1172\/jci.insight.122146","volume":"3","author":"F Vecchio","year":"2018","unstructured":"F. Vecchio, N. Lo Buono, A. Stabilini, L. Nigi, M.J. Dufort, S. Geyer et al., Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight. 3(18), e122146 (2018). https:\/\/doi.org\/10.1172\/jci.insight.122146","journal-title":"JCI Insight"},{"key":"4637_CR56","doi-asserted-by":"publisher","first-page":"930553","DOI":"10.3389\/fimmu.2022.930553","volume":"13","author":"A Petrelli","year":"2022","unstructured":"A. Petrelli, S.K. Popp, R. Fukuda, C.R. Parish, E. Bosi, C.J. Simeonovic, The Contribution of Neutrophils and NETs to the Development of Type 1 Diabetes. Front. Immunol. 13, 930553 (2022). https:\/\/doi.org\/10.3389\/fimmu.2022.930553","journal-title":"Front. Immunol."},{"issue":"1","key":"4637_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00125-020-05298-y","volume":"64","author":"A Carr\u00e9","year":"2021","unstructured":"A. Carr\u00e9, S.J. Richardson, E. Larger, R. Mallone, Presumption of guilt for T cells in type 1 diabetes: lead culprits or partners in crime depending on age of onset? Diabetologia. 64(1), 15\u201325 (2021). https:\/\/doi.org\/10.1007\/s00125-020-05298-y","journal-title":"Diabetologia"},{"issue":"11","key":"4637_CR58","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.2337\/db14-0365","volume":"63","author":"S Arif","year":"2014","unstructured":"S. Arif, P. Leete, V. Nguyen, K. Marks, N.M. Nor, M. Estorninho et al., Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes. Diabetes. 63(11), 3835\u20133845 (2014). https:\/\/doi.org\/10.2337\/db14-0365","journal-title":"Diabetes"},{"issue":"5","key":"4637_CR59","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.2337\/db15-1615","volume":"65","author":"P Leete","year":"2016","unstructured":"P. Leete, A. Willcox, L. Krogvold, K. Dahl-J\u00f8rgensen, A.K. Foulis, S.J. Richardson et al., Differential Insulitic Profiles Determine the Extent of \u03b2-Cell Destruction and the Age at Onset of Type 1 Diabetes. Diabetes. 65(5), 1362\u20131369 (2016). https:\/\/doi.org\/10.2337\/db15-1615","journal-title":"Diabetes"},{"issue":"6","key":"4637_CR60","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00125-020-05115-6","volume":"63","author":"P Leete","year":"2020","unstructured":"TIGI study team, P. Leete, R.A. Oram, T.J. McDonald, B.M. Shields, C. Ziller et al., Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. Diabetologia. 63(6), 1258\u20131267 (2020). https:\/\/doi.org\/10.1007\/s00125-020-05115-6","journal-title":"Diabetologia"},{"issue":"10","key":"4637_CR61","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.2337\/dc16-0360","volume":"39","author":"W Hao","year":"2016","unstructured":"W. Hao, S. Gitelman, L.A. DiMeglio, D. Boulware, C.J. Greenbaum, for the Type 1 Diabetes TrialNet Study Group, Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care. 39(10), 1664\u20131670 (2016). https:\/\/doi.org\/10.2337\/dc16-0360","journal-title":"Diabetes Care"},{"issue":"2","key":"4637_CR62","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2337\/db12-0207","volume":"62","author":"Z Zhou","year":"2013","unstructured":"Z. Zhou, Y. Xiang, L. Ji, W. Jia, G. Ning, G. Huang et al., Frequency, Immunogenetics, and Clinical Characteristics of Latent Autoimmune Diabetes in China (LADA China Study). Diabetes. 62(2), 543\u2013550 (2013). https:\/\/doi.org\/10.2337\/db12-0207","journal-title":"Diabetes"},{"issue":"2","key":"4637_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1651-2227.1977.tb07830.x","volume":"66","author":"J Ludvigsson","year":"1977","unstructured":"J. Ludvigsson, L.G. Heding, Y. Larsson, E. Leander, C-PEPTIDE IN JUVENILE DIABETICS, BEYOND THE POSTINITIAL REMISSION PERIOD Relation to Clinical Manifestations at Onset of Diabetes, Remission and Diabetic Control. Acta Paediatr. 66(2), 177\u2013184 (1977). https:\/\/doi.org\/10.1111\/j.1651-2227.1977.tb07830.x","journal-title":"Acta Paediatr."},{"issue":"1","key":"4637_CR64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1210\/jcem-65-1-30","volume":"65","author":"THE DCCT RESEARCH GROUP","year":"1987","unstructured":"THE DCCT RESEARCH GROUP, Effects of Age, Duration and Treatment of Insulin-Dependent Diabetes Mellitus on Residual \u03b2 -Cell Function: Observations During Eligibility Testing for the Diabetes Control and Complications Trial (DCCT). J. Clin. Endocrinol. Metabolism. 65(1), 30\u201336 (1987). https:\/\/doi.org\/10.1210\/jcem-65-1-30","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"2","key":"4637_CR65","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2337\/db13-0881","volume":"63","author":"JM Lachin","year":"2014","unstructured":"J.M. Lachin, P. McGee, J.P. Palmer, for the DCCT\/EDIC Research Group, Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial. Diabetes. 63(2), 739\u2013748 (2014). https:\/\/doi.org\/10.2337\/db13-0881","journal-title":"Diabetes"},{"issue":"7","key":"4637_CR66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.7326\/0003-4819-128-7-199804010-00001","volume":"128","author":"Effect of Intensive Therapy on Residual \u03b2-Cell Function","year":"1998","unstructured":"Effect of Intensive Therapy on Residual \u03b2-Cell Function, in Patients with Type 1 Diabetes in the Diabetes Control and Complications Trial: A Randomized, Controlled Trial. Ann. Intern. Med. 128(7), 517\u2013523 (1998). https:\/\/doi.org\/10.7326\/0003-4819-128-7-199804010-00001","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"4637_CR67","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11892-018-1083-4","volume":"18","author":"P Leete","year":"2018","unstructured":"P. Leete, R. Mallone, S.J. Richardson, J.M. Sosenko, M.J. Redondo, C. Evans-Molina, The Effect of Age on the Progression and Severity of Type 1 Diabetes: Potential Effects on Disease Mechanisms. Curr. Diab Rep. 18(11), 115 (2018). https:\/\/doi.org\/10.1007\/s11892-018-1083-4","journal-title":"Curr. Diab Rep."},{"issue":"1","key":"4637_CR68","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00125-013-3067-x","volume":"57","author":"RA Oram","year":"2014","unstructured":"R.A. Oram, A.G. Jones, R.E.J. Besser, B.A. Knight, B.M. Shields, R.J. Brown et al., The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia. 57(1), 187\u2013191 (2014). https:\/\/doi.org\/10.1007\/s00125-013-3067-x","journal-title":"Diabetologia"},{"issue":"10","key":"4637_CR69","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/dme.12504","volume":"31","author":"P McGee","year":"2014","unstructured":"P. McGee, M. Steffes, M. Nowicki, M. Bayless, R. Gubitosi-Klug, P. Cleary et al., Insulin secretion measured by stimulated C\u2010peptide in long\u2010established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)\/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabet. Med. 31(10), 1264\u20131268 (2014). https:\/\/doi.org\/10.1111\/dme.12504","journal-title":"Diabet. Med."},{"issue":"11","key":"4637_CR70","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.2337\/db10-0676","volume":"59","author":"HA Keenan","year":"2010","unstructured":"H.A. Keenan, J.K. Sun, J. Levine, A. Doria, L.P. Aiello, G. Eisenbarth et al., Residual Insulin Production and Pancreatic \u03b2-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study. Diabetes. 59(11), 2846\u20132853 (2010). https:\/\/doi.org\/10.2337\/db10-0676","journal-title":"Diabetes"},{"issue":"1\u20132","key":"4637_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.imlet.2014.02.006","volume":"159","author":"J Ludvigsson","year":"2014","unstructured":"J. Ludvigsson, Combination therapy for preservation of beta cell function in Type 1 diabetes: New attitudes and strategies are needed! Immunol. Lett. 159(1\u20132), 30\u201335 (2014). https:\/\/doi.org\/10.1016\/j.imlet.2014.02.006","journal-title":"Immunol. Lett."},{"issue":"4","key":"4637_CR72","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00125-019-4822-4","volume":"62","author":"RA Oram","year":"2019","unstructured":"R.A. Oram, E.K. Sims, C. Evans-Molina, Beta cells in type 1 diabetes: mass and function; sleeping or dead? Diabetologia. 62(4), 567\u2013577 (2019). https:\/\/doi.org\/10.1007\/s00125-019-4822-4","journal-title":"Diabetologia"},{"issue":"2","key":"4637_CR73","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/pedi.12135","volume":"15","author":"DE VanBuecken","year":"2014","unstructured":"D.E. VanBuecken, C.J. Greenbaum, Residual C-peptide in type 1 diabetes: what do we really know? Residual C-peptide in T1D. Pediatr. Diabetes. 15(2), 84\u201390 (2014). https:\/\/doi.org\/10.1111\/pedi.12135","journal-title":"Pediatr. Diabetes"},{"issue":"21","key":"4637_CR74","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1056\/NEJM198605223142106","volume":"314","author":"JS Flier","year":"1986","unstructured":"J.S. Flier, L.H. Underhill, G.S. Eisenbarth, I. Type, Diabetes Mellitus, N Engl. J. Med. 314(21), 1360\u20131368 (1986). https:\/\/doi.org\/10.1056\/NEJM198605223142106","journal-title":"N Engl. J. Med."},{"issue":"6","key":"4637_CR75","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.381","volume":"41","author":"JC Barrett","year":"2009","unstructured":"The Type 1 Diabetes Genetics Consortium, J.C. Barrett, D.G. Clayton, P. Concannon, B. Akolkar, J.D. Cooper et al., Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41(6), 703\u2013707 (2009). https:\/\/doi.org\/10.1038\/ng.381","journal-title":"Nat. Genet."},{"issue":"4","key":"4637_CR76","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/db07-1331","volume":"57","author":"H Erlich","year":"2008","unstructured":"H. Erlich, A.M. Valdes, J. Noble, J.A. Carlson, M. Varney, P. Concannon et al., HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk. Diabetes. 57(4), 1084\u20131092 (2008). https:\/\/doi.org\/10.2337\/db07-1331","journal-title":"Diabetes"},{"issue":"1","key":"4637_CR77","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cmet.2019.11.017","volume":"31","author":"JT Warshauer","year":"2020","unstructured":"J.T. Warshauer, J.A. Bluestone, M.S. Anderson, New Frontiers in the Treatment of Type 1 Diabetes. Cell Metabol. 31(1), 46\u201361 (2020). https:\/\/doi.org\/10.1016\/j.cmet.2019.11.017","journal-title":"Cell Metabol."},{"key":"4637_CR78","doi-asserted-by":"publisher","unstructured":"G. Salame, V. Hakim, C. Dagher, R.M. Daou, A.E. Dada, L. Nassif et al., Immunotherapy as a treatment for type 1 diabetes mellitus in children and young adults: A comprehensive systematic review and meta-analysis. Fiorina P, editor. PLoS ONE. 2025;20(4):e0321727. https:\/\/doi.org\/10.1371\/journal.pone.0321727","DOI":"10.1371\/journal.pone.0321727"},{"issue":"1","key":"4637_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2337\/dc19-0803","volume":"43","author":"JRJ Inshaw","year":"2020","unstructured":"J.R.J. Inshaw, A.J. Cutler, D.J.M. Crouch, L.S. Wicker, J.A. Todd, Genetic Variants Predisposing Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That Function in the Immune System and in Pancreatic \u03b2-Cells. Diabetes Care. 43(1), 169\u2013177 (2020). https:\/\/doi.org\/10.2337\/dc19-0803","journal-title":"Diabetes Care"},{"issue":"3","key":"4637_CR80","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00125-024-06338-7","volume":"68","author":"MJ Redondo","year":"2025","unstructured":"M.J. Redondo, D. Cuthbertson, A.K. Steck, K.C. Herold, R. Oram, M. Atkinson et al., Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes. Diabetologia. 68(3), 588\u2013601 (2025). https:\/\/doi.org\/10.1007\/s00125-024-06338-7","journal-title":"Diabetologia"},{"issue":"23","key":"4637_CR81","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1001\/jama.2013.6285","volume":"309","author":"AG Ziegler","year":"2013","unstructured":"A.G. Ziegler, M. Rewers, O. Simell, T. Simell, J. Lempainen, A. Steck et al., Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children. JAMA 309(23), 2473 (2013). https:\/\/doi.org\/10.1001\/jama.2013.6285","journal-title":"JAMA"},{"issue":"6","key":"4637_CR82","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.2337\/db15-1058","volume":"65","author":"KA McLaughlin","year":"2016","unstructured":"K.A. McLaughlin, C.C. Richardson, A. Ravishankar, C. Brigatti, D. Liberati, V. Lampasona et al., Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes. Diabetes. 65(6), 1690\u20131698 (2016). https:\/\/doi.org\/10.2337\/db15-1058","journal-title":"Diabetes"},{"issue":"1","key":"4637_CR83","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1038\/s41467-024-47918-w","volume":"15","author":"I Starskaia","year":"2024","unstructured":"I. Starskaia, M. Valta, S. Pietil\u00e4, T. Suomi, S. Pahkuri, U.U. Kalim et al., Distinct cellular immune responses in children en route to type 1 diabetes with different first-appearing autoantibodies. Nat. Commun. 15(1), 3810 (2024). https:\/\/doi.org\/10.1038\/s41467-024-47918-w","journal-title":"Nat. Commun."},{"issue":"8","key":"4637_CR84","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.2337\/dc24-0198","volume":"47","author":"M Ghalwash","year":"2024","unstructured":"M. Ghalwash, V. Anand, K. Ng, J.L. Dunne, O. Lou, M. Lundgren et al., Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles. Diabetes Care. 47(8), 1424\u20131431 (2024). https:\/\/doi.org\/10.2337\/dc24-0198","journal-title":"Diabetes Care"},{"issue":"1","key":"4637_CR85","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2337\/db18-0594","volume":"68","author":"D Endesfelder","year":"2019","unstructured":"D. Endesfelder, W. Zu Castell, E. Bonifacio, M. Rewers, W.A. Hagopian, J.X. She et al., Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children. Diabetes. 68(1), 119\u2013130 (2019). https:\/\/doi.org\/10.2337\/db18-0594","journal-title":"Diabetes"},{"issue":"5","key":"4637_CR86","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/j.1464-5491.1992.tb01811.x","volume":"9","author":"L Nystr\u00f6m","year":"1992","unstructured":"L. Nystr\u00f6m, J. \u00d6stman, S. Wall, L. Wibell, The Diabetes Incidence Study in Sweden (DISS) Group, Mortality of All Incident Cases of Diabetes Mellitus in Sweden Diagnosed 1983\u20131987 at Age 15\u201334 Years. Diabet. Med. 9(5), 422\u2013427 (1992). https:\/\/doi.org\/10.1111\/j.1464-5491.1992.tb01811.x","journal-title":"Diabet. Med."},{"issue":"10","key":"4637_CR87","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(23)00190-0","volume":"11","author":"LA Allen","year":"2023","unstructured":"L.A. Allen, P.N. Taylor, K.M. Gillespie, R.A. Oram, C.M. Dayan, Maternal type 1 diabetes and relative protection against offspring transmission. Lancet Diabetes Endocrinol. 11(10), 755\u2013767 (2023). https:\/\/doi.org\/10.1016\/S2213-8587(23)00190-0","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"4637_CR88","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1210\/jc.2017-01490","volume":"102","author":"CT Ferrara","year":"2017","unstructured":"C.T. Ferrara, S.M. Geyer, C. Evans-Molina, I.M. Libman, D.J. Becker, J.M. Wentworth et al., The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. J. Clin. Endocrinol. Metabolism. 102(12), 4596\u20134603 (2017). https:\/\/doi.org\/10.1210\/jc.2017-01490","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"3","key":"4637_CR89","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2337\/dc19-1167","volume":"43","author":"C Ferrara-Cook","year":"2020","unstructured":"C. Ferrara-Cook, S.M. Geyer, C. Evans-Molina, I.M. Libman, D.J. Becker, S.E. Gitelman et al., Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents. Diabetes Care. 43(3), 580\u2013587 (2020). https:\/\/doi.org\/10.2337\/dc19-1167","journal-title":"Diabetes Care"},{"issue":"9","key":"4637_CR90","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00125-022-05722-5","volume":"65","author":"I Zucker","year":"2022","unstructured":"I. Zucker, Y. Zloof, A. Bardugo, A.M. Tsur, M. Lutski, Y. Cohen et al., Obesity in late adolescence and incident type 1 diabetes in young adulthood. Diabetologia. 65(9), 1473\u20131482 (2022). https:\/\/doi.org\/10.1007\/s00125-022-05722-5","journal-title":"Diabetologia"},{"issue":"6","key":"4637_CR91","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00125-016-3924-5","volume":"59","author":"FA Meah","year":"2016","unstructured":"for the Type 1 Diabetes TrialNet Study Group, F.A. Meah, L.A. DiMeglio, C.J. Greenbaum, J.S. Blum, J.M. Sosenko et al., The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. Diabetologia. 59(6), 1186\u20131195 (2016). https:\/\/doi.org\/10.1007\/s00125-016-3924-5","journal-title":"Diabetologia"},{"issue":"1","key":"4637_CR92","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12933-023-02007-y","volume":"22","author":"M Nitecki","year":"2023","unstructured":"M. Nitecki, H.C. Gerstein, Y. Balmakov, E. Tsur, V. Babushkin, T. Michaeli et al., High BMI and the risk for incident type 1 Diabetes Mellitus: a systematic review and meta-analysis of aggregated cohort studies. Cardiovasc. Diabetol. 22(1), 300 (2023). https:\/\/doi.org\/10.1186\/s12933-023-02007-y","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"4637_CR93","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40618-024-02497-x","volume":"48","author":"V Codazzi","year":"2024","unstructured":"V. Codazzi, V. Salvatore, F. Ragogna, I. Marzinotto, A. Anselmo, N. Baldoni et al., Metabolic, genetic and immunological features of relatives of type 1 diabetes patients with elevated insulin resistance. J. Endocrinol. Invest. 48(3), 765\u2013775 (2024). https:\/\/doi.org\/10.1007\/s40618-024-02497-x","journal-title":"J. Endocrinol. Invest."},{"issue":"9","key":"4637_CR94","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.autrev.2015.05.002","volume":"14","author":"K Kakleas","year":"2015","unstructured":"K. Kakleas, A. Soldatou, F. Karachaliou, K. Karavanaki, Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM). Autoimmun. rev. 14(9), 781\u2013797 (2015). https:\/\/doi.org\/10.1016\/j.autrev.2015.05.002","journal-title":"Autoimmun. rev."},{"key":"4637_CR95","doi-asserted-by":"publisher","unstructured":"E.A. Grasso, F. Chiarelli, Type 1 Diabetes and Other Autoimmune Disorders in Children. Kawamura T, editor. Pediatric Diabetes. 2024;2024:1\u201314. https:\/\/doi.org\/10.1155\/2024\/5082064","DOI":"10.1155\/2024\/5082064"},{"issue":"9","key":"4637_CR96","doi-asserted-by":"publisher","first-page":"116174","DOI":"10.1016\/j.celrep.2025.116174","volume":"44","author":"MK Huber","year":"2025","unstructured":"M.K. Huber, A.E. Widener, A.E. Cuaycal, D. Smurlick, E.A. Butterworth, N.I. Lenchik et al., Beta cell dysfunction occurs independently of insulitis in type 1 diabetes pathogenesis. Cell. Rep. 44(9), 116174 (2025). https:\/\/doi.org\/10.1016\/j.celrep.2025.116174","journal-title":"Cell. Rep."},{"issue":"10","key":"4637_CR97","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00125-020-05176-7","volume":"63","author":"R Mallone","year":"2020","unstructured":"R. Mallone, D.L. Eizirik, Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1. diabetes? Diabetologia. 63(10), 1999\u20132006 (2020). https:\/\/doi.org\/10.1007\/s00125-020-05176-7","journal-title":"diabetes? Diabetologia"},{"issue":"3","key":"4637_CR98","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","volume":"17","author":"BO Roep","year":"2021","unstructured":"B.O. Roep, S. Thomaidou, Van R. Tienhoven, A. Zaldumbide, Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?). Nat. Rev. Endocrinol. 17(3), 150\u2013161 (2021). https:\/\/doi.org\/10.1038\/s41574-020-00443-4","journal-title":"Nat. Rev. Endocrinol."},{"key":"4637_CR99","doi-asserted-by":"publisher","first-page":"756548","DOI":"10.3389\/fimmu.2021.756548","volume":"12","author":"E Toren","year":"2021","unstructured":"E. Toren, K.S. Burnette, R.R. Banerjee, C.S. Hunter, H.M. Tse, Partners in Crime: Beta-Cells and Autoimmune Responses Complicit in Type 1 Diabetes Pathogenesis. Front. Immunol. 12, 756548 (2021). https:\/\/doi.org\/10.3389\/fimmu.2021.756548","journal-title":"Front. Immunol."},{"issue":"10","key":"4637_CR100","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11892-016-0783-x","volume":"16","author":"RG Mirmira","year":"2016","unstructured":"R.G. Mirmira, E.K. Sims, F. Syed, C. Evans-Molina, Biomarkers of \u03b2-Cell Stress and Death in Type 1 Diabetes. Curr. Diab Rep. 16(10), 95 (2016). https:\/\/doi.org\/10.1007\/s11892-016-0783-x","journal-title":"Curr. Diab Rep."},{"issue":"4","key":"4637_CR101","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/MED.0000000000000548","volume":"27","author":"EK Sims","year":"2020","unstructured":"E.K. Sims, R.G. Mirmira, C. Evans-Molina, The role of beta-cell dysfunction in early type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 27(4), 215\u2013224 (2020). https:\/\/doi.org\/10.1097\/MED.0000000000000548","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"3","key":"4637_CR102","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1365-2249.2009.04087.x","volume":"159","author":"BO Roep","year":"2010","unstructured":"B.O. Roep, F.S. Kleijwegt, Van A.G.S. Halteren, V. Bonato, U. Boggi, F. Vendrame et al., Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin. Exp. Immunol. 159(3), 338\u2013343 (2010). https:\/\/doi.org\/10.1111\/j.1365-2249.2009.04087.x","journal-title":"Clin. Exp. Immunol."},{"issue":"9","key":"4637_CR103","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00125-012-2604-3","volume":"55","author":"I Marhfour","year":"2012","unstructured":"I. Marhfour, X.M. Lopez, D. Lefkaditis, I. Salmon, F. Allagnat, S.J. Richardson et al., Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia. 55(9), 2417\u20132420 (2012). https:\/\/doi.org\/10.1007\/s00125-012-2604-3","journal-title":"Diabetologia"},{"key":"4637_CR104","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.coi.2016.09.007","volume":"43","author":"BO Roep","year":"2016","unstructured":"B.O. Roep, M.J. Kracht, Van M. Lummel, A. Zaldumbide, A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes. Curr. Opin. Immunol. 43, 67\u201373 (2016). https:\/\/doi.org\/10.1016\/j.coi.2016.09.007","journal-title":"Curr. Opin. Immunol."},{"key":"4637_CR105","doi-asserted-by":"publisher","first-page":"1112858","DOI":"10.3389\/fimmu.2023.1112858","volume":"14","author":"BO Roep","year":"2023","unstructured":"B.O. Roep, The need and benefit of immune monitoring to define patient and disease heterogeneity, mechanisms of therapeutic action and efficacy of intervention therapy for precision medicine in type 1 diabetes. Front. Immunol. 14, 1112858 (2023). https:\/\/doi.org\/10.3389\/fimmu.2023.1112858","journal-title":"Front. Immunol."},{"issue":"3","key":"4637_CR106","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1210\/clinem\/dgae844","volume":"110","author":"PW Franks","year":"2025","unstructured":"P.W. Franks, S.S. Rich, B. Linder, N.A. Zaghloul, W.T. Cefalu, A Research Roadmap to Address the Heterogeneity of Diabetes and Advance Precision Medicine. J. Clin. Endocrinol. Metabolism. 110(3), 601\u2013610 (2025). https:\/\/doi.org\/10.1210\/clinem\/dgae844","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"4","key":"4637_CR107","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40265-025-02150-8","volume":"85","author":"TP Foster","year":"2025","unstructured":"T.P. Foster, B.S. Bruggeman, M.J. Haller, Emerging Immunotherapies for Disease Modification of Type 1 Diabetes. Drugs. 85(4), 457\u2013473 (2025). https:\/\/doi.org\/10.1007\/s40265-025-02150-8","journal-title":"Drugs"},{"key":"4637_CR108","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fendo.2020.00248","volume":"11","author":"M Primavera","year":"2020","unstructured":"M. Primavera, C. Giannini, F. Chiarelli, Prediction and Prevention of Type 1 Diabetes. Front. Endocrinol. 11, 248 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.00248","journal-title":"Front. Endocrinol."},{"issue":"1","key":"4637_CR109","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-8587(18)30109-8","volume":"7","author":"BO Roep","year":"2019","unstructured":"B.O. Roep, D.C.S. Wheeler, M. Peakman, Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabetes Endocrinol. 7(1), 65\u201374 (2019). https:\/\/doi.org\/10.1016\/S2213-8587(18)30109-8","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"4637_CR110","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11892-017-0878-z","volume":"17","author":"RN Bone","year":"2017","unstructured":"R.N. Bone, C. Evans-Molina, Combination Immunotherapy for Type 1 Diabetes. Curr. Diab Rep. 17(7), 50 (2017). https:\/\/doi.org\/10.1007\/s11892-017-0878-z","journal-title":"Curr. Diab Rep."},{"issue":"7","key":"4637_CR111","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1111\/dom.15581","volume":"26","author":"G Grando Alves","year":"2024","unstructured":"G. Grando Alves, L. Cunha, R. Henkes Machado, V. Lins De Menezes, Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials. Diabetes Obes. Metabolism. 26(7), 2652\u20132661 (2024). https:\/\/doi.org\/10.1111\/dom.15581","journal-title":"Diabetes Obes. Metabolism"},{"issue":"5","key":"4637_CR112","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2337\/dc22-2200","volume":"46","author":"WE Russell","year":"2023","unstructured":"W.E. Russell, B.N. Bundy, M.S. Anderson, L.A. Cooney, S.E. Gitelman, R.S. Goland et al., Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care. 46(5), 1005\u20131013 (2023). https:\/\/doi.org\/10.2337\/dc22-2200","journal-title":"Diabetes Care"},{"issue":"23","key":"4637_CR113","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","volume":"389","author":"M Waibel","year":"2023","unstructured":"M. Waibel, J.M. Wentworth, M. So, J.J. Couper, F.J. Cameron, R.J. MacIsaac et al., Baricitinib and \u03b2-Cell Function in Patients with New-Onset Type 1 Diabetes. N Engl. J. Med. 389(23), 2140\u20132150 (2023). https:\/\/doi.org\/10.1056\/NEJMoa2306691","journal-title":"N Engl. J. Med."},{"issue":"10","key":"4637_CR114","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00125-025-06490-8","volume":"68","author":"L Degroote","year":"2025","unstructured":"L. Degroote, P.J. Martens, M. Viaene, Y. Heremans, G. Leuckx, N. Geukens et al., Verapamil and low-dose anti-mouse thymocyte globulin combination therapy stably reverses recent-onset type 1 diabetes in NOD mice by acting on the beta cell and immune axes. Diabetologia. 68(10), 2263\u20132276 (2025). https:\/\/doi.org\/10.1007\/s00125-025-06490-8","journal-title":"Diabetologia"},{"key":"4637_CR115","doi-asserted-by":"publisher","first-page":"116808","DOI":"10.1016\/j.biopha.2024.116808","volume":"176","author":"M Nabi-Afjadi","year":"2024","unstructured":"M. Nabi-Afjadi, S. Ostadhadi, M. Liaghat, A.P. Pasupulla, S. Masoumi, F. Aziziyan et al., Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments. Biomed. Pharmacother. 176, 116808 (2024). https:\/\/doi.org\/10.1016\/j.biopha.2024.116808","journal-title":"Biomed. Pharmacother."},{"issue":"416","key":"4637_CR116","doi-asserted-by":"publisher","first-page":"eaam7543","DOI":"10.1126\/scitranslmed.aam7543","volume":"9","author":"M Ben Nasr","year":"2017","unstructured":"M. Ben Nasr, S. Tezza, F. D\u2019Addio, C. Mameli, V. Usuelli, A. Maestroni et al., PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci. Transl Med. 9(416), eaam7543 (2017). https:\/\/doi.org\/10.1126\/scitranslmed.aam7543","journal-title":"Sci. Transl Med."},{"issue":"3","key":"4637_CR117","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/1750743X.2025.2473311","volume":"17","author":"R Jeun","year":"2025","unstructured":"R. Jeun, Immunotherapies for prevention and treatment of type 1 diabetes. Immunotherapy. 17(3), 201\u2013210 (2025). https:\/\/doi.org\/10.1080\/1750743X.2025.2473311","journal-title":"Immunotherapy"},{"issue":"10","key":"4637_CR118","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41574-025-01128-6","volume":"21","author":"FL Henriques","year":"2025","unstructured":"F.L. Henriques, I. Buckle, J.M. Forbes, Type 1 diabetes mellitus prevention: present and future. Nat. Rev. Endocrinol. 21(10), 608\u2013622 (2025). https:\/\/doi.org\/10.1038\/s41574-025-01128-6","journal-title":"Nat. Rev. Endocrinol."},{"key":"4637_CR119","doi-asserted-by":"publisher","first-page":"666795","DOI":"10.3389\/fendo.2021.666795","volume":"12","author":"H Zirpel","year":"2021","unstructured":"H. Zirpel, B.O. Roep, Islet-Resident Dendritic Cells and Macrophages in Type 1 Diabetes: In Search of Bigfoot\u2019s Print. Front. Endocrinol. 12, 666795 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.666795","journal-title":"Front. Endocrinol."},{"issue":"6","key":"4637_CR120","doi-asserted-by":"publisher","first-page":"e20192362","DOI":"10.1084\/jem.20192362","volume":"217","author":"PN Zakharov","year":"2020","unstructured":"P.N. Zakharov, H. Hu, X. Wan, E.R. Unanue, Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes. J. Exp. Med. 217(6), e20192362 (2020). https:\/\/doi.org\/10.1084\/jem.20192362","journal-title":"J. Exp. Med."},{"issue":"49","key":"4637_CR121","doi-asserted-by":"publisher","first-page":"31319","DOI":"10.1073\/pnas.2019743117","volume":"117","author":"H Hu","year":"2020","unstructured":"H. Hu, P.N. Zakharov, O.J. Peterson, E.R. Unanue, Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice. Proc. Natl. Acad. Sci. USA 117(49), 31319\u201331330 (2020). https:\/\/doi.org\/10.1073\/pnas.2019743117","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"4637_CR122","doi-asserted-by":"publisher","first-page":"e3064","DOI":"10.1002\/dmrr.3064","volume":"35","author":"J Huang","year":"2019","unstructured":"J. Huang, Y. Xiao, P. Zheng, W. Zhou, Y. Wang, G. Huang et al., Distinct neutrophil counts and functions in newly diagnosed type 1 diabetes, latent autoimmune diabetes in adults, and type 2 diabetes. Diabetes Metabolism Res. 35(1), e3064 (2019). https:\/\/doi.org\/10.1002\/dmrr.3064","journal-title":"Diabetes Metabolism Res."},{"issue":"4","key":"4637_CR123","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3390\/biom15040505","volume":"15","author":"L Nigi","year":"2025","unstructured":"L. Nigi, E. Pedace, F. Dotta, G. Sebastiani, Neutrophils in Type 1 Diabetes: Untangling the Intricate Web of Pathways and Hypothesis. Biomolecules. 15(4), 505 (2025). https:\/\/doi.org\/10.3390\/biom15040505","journal-title":"Biomolecules"},{"issue":"9","key":"4637_CR124","doi-asserted-by":"publisher","first-page":"eabd6527","DOI":"10.1126\/sciadv.abd6527","volume":"7","author":"PS Apaolaza","year":"2021","unstructured":"P.S. Apaolaza, D. Balcacean, J. Zapardiel-Gonzalo, G. Nelson, N. Lenchik, P. Akhbari et al., Islet expression of type I interferon response sensors is associated with immune infiltration and viral infection in type 1 diabetes. Sci. Adv. 7(9), eabd6527 (2021). https:\/\/doi.org\/10.1126\/sciadv.abd6527","journal-title":"Sci. Adv."},{"issue":"44","key":"4637_CR125","doi-asserted-by":"publisher","first-page":"15995","DOI":"10.1073\/pnas.0508122102","volume":"102","author":"LF Lee","year":"2005","unstructured":"L.F. Lee, B. Xu, S.A. Michie, G.F. Beilhack, T. Warganich, S. Turley et al., The role of TNF-\u03b1 in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: Analysis of dendritic cell maturation. Proc. Natl. Acad. Sci. USA 102(44), 15995\u201316000 (2005). https:\/\/doi.org\/10.1073\/pnas.0508122102","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"4637_CR126","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1084\/jem.191.2.225","volume":"191","author":"EA Green","year":"2000","unstructured":"E.A. Green, F.S. Wong, K. Eshima, C. Mora, R.A. Flavell, Neonatal Tumor Necrosis Factor \u03b1 Promotes Diabetes in Nonobese Diabetic Mice by Cd154-Independent Antigen Presentation to Cd8\u2009+\u2009T Cells. J. Exp. Med. 191(2), 225\u2013238 (2000). https:\/\/doi.org\/10.1084\/jem.191.2.225","journal-title":"J. Exp. Med."},{"key":"4637_CR127","doi-asserted-by":"publisher","unstructured":"Y. Qiao, Y. Chen, Y. ling, Pan hong, F. Tian, Y. Xu, X. Zhang, xi et al., The change of serum tumor necrosis factor alpha in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. Ariga H, editor. PLoS ONE. 2017;12(4):e0176157. https:\/\/doi.org\/10.1371\/journal.pone.0176157","DOI":"10.1371\/journal.pone.0176157"},{"key":"4637_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2987901","volume":"2019","author":"K Wang","year":"2019","unstructured":"K. Wang, F. Li, Y. Cui, C. Cui, Z. Cao, K. Xu et al., The Association between Depression and Type 1 Diabetes Mellitus: Inflammatory Cytokines as Ferrymen in between? Mediat. Inflamm. 2019, 1\u201311 (2019). https:\/\/doi.org\/10.1155\/2019\/2987901","journal-title":"Mediat. Inflamm."},{"issue":"3","key":"4637_CR129","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12026-022-09355-z","volume":"71","author":"BA Ozgur","year":"2023","unstructured":"B.A. Ozgur, S.A. Cinar, E. Coskunpinar, A. Yilmaz, D. Altunkanat, G. Deniz et al., The role of cytokines and T-bet, GATA3, ROR-\u03b3t, and FOXP3 transcription factors of T cell subsets in the natural clinical progression of Type 1 Diabetes. Immunol. Res. 71(3), 451\u2013462 (2023). https:\/\/doi.org\/10.1007\/s12026-022-09355-z","journal-title":"Immunol. Res."},{"issue":"1","key":"4637_CR130","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13098-025-01582-2","volume":"17","author":"M Zhou","year":"2025","unstructured":"M. Zhou, Q. Shen, B. Li, JAK inhibitors: a new choice for diabetes mellitus? Diabetol. Metab. Syndr. 17(1), 33 (2025). https:\/\/doi.org\/10.1186\/s13098-025-01582-2","journal-title":"Diabetol. Metab. Syndr."},{"issue":"6","key":"4637_CR131","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/db16-1250","volume":"66","author":"PM Trivedi","year":"2017","unstructured":"P.M. Trivedi, K.L. Graham, N.A. Scott, M.R. Jenkins, S. Majaw, R.M. Sutherland et al., Repurposed JAK1\/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice. Diabetes. 66(6), 1650\u20131660 (2017). https:\/\/doi.org\/10.2337\/db16-1250","journal-title":"Diabetes"},{"issue":"7","key":"4637_CR132","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2337\/dc09-0054","volume":"32","author":"L Mastrandrea","year":"2009","unstructured":"L. Mastrandrea, J. Yu, T. Behrens, J. Buchlis, C. Albini, S. Fourtner et al., Etanercept Treatment in Children With New-Onset Type 1 Diabetes. Diabetes Care. 32(7), 1244\u20131249 (2009). https:\/\/doi.org\/10.2337\/dc09-0054","journal-title":"Diabetes Care"},{"issue":"21","key":"4637_CR133","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","volume":"383","author":"T Quattrin","year":"2020","unstructured":"T. Quattrin, M.J. Haller, A.K. Steck, E.I. Felner, Y. Li, Y. Xia et al., Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. N Engl. J. Med. 383(21), 2007\u20132017 (2020). https:\/\/doi.org\/10.1056\/NEJMoa2006136","journal-title":"N Engl. J. Med."},{"issue":"3","key":"4637_CR134","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2337\/dc22-0908","volume":"46","author":"MR Rigby","year":"2023","unstructured":"M.R. Rigby, B. Hayes, Y. Li, F. Vercruysse, J.A. Hedrick, T. Quattrin, Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Diabetes Care. 46(3), 561\u2013569 (2023). https:\/\/doi.org\/10.2337\/dc22-0908","journal-title":"Diabetes Care"},{"issue":"10","key":"4637_CR135","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.2337\/dc23-0675","volume":"46","author":"KC Herold","year":"2023","unstructured":"K.C. Herold, S.E. Gitelman, P.A. Gottlieb, L.A. Knecht, R. Raymond, E.L. Ramos, Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves \u03b2-Cell Function. Diabetes Care. 46(10), 1848\u20131856 (2023). https:\/\/doi.org\/10.2337\/dc23-0675","journal-title":"Diabetes Care"},{"issue":"7","key":"4637_CR136","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2337\/dc24-2908","volume":"48","author":"LM Jacobsen","year":"2025","unstructured":"L.M. Jacobsen, J.L. Felton, B.M. Nathan, C. Speake, J. Krischer, K.C. Herold, Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding. Diabetes Care. 48(7), 1112\u20131124 (2025). https:\/\/doi.org\/10.2337\/dc24-2908","journal-title":"Diabetes Care"},{"key":"4637_CR137","doi-asserted-by":"publisher","first-page":"1533748","DOI":"10.3389\/fendo.2025.1533748","volume":"16","author":"MR Saleem","year":"2025","unstructured":"M.R. Saleem, M.T. Khan, Teplizumab: a promising intervention for delaying type 1 diabetes progression. Front. Endocrinol. 16, 1533748 (2025). https:\/\/doi.org\/10.3389\/fendo.2025.1533748","journal-title":"Front. Endocrinol."},{"issue":"7","key":"4637_CR138","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"K.C. Herold, B.N. Bundy, S.A. Long, J.A. Bluestone, L.A. DiMeglio, M.J. Dufort et al., An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl. J. Med. 381(7), 603\u2013613 (2019). https:\/\/doi.org\/10.1056\/NEJMoa1902226","journal-title":"N Engl. J. Med."},{"issue":"23","key":"4637_CR139","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","volume":"389","author":"EL Ramos","year":"2023","unstructured":"E.L. Ramos, C.M. Dayan, L. Chatenoud, Z. Sumnik, K.M. Simmons, A. Szypowska et al., Teplizumab and \u03b2-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl. J. Med. 389(23), 2151\u20132161 (2023). https:\/\/doi.org\/10.1056\/NEJMoa2308743","journal-title":"N Engl. J. Med."},{"issue":"2","key":"4637_CR140","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/dc13-0626","volume":"37","author":"MD Pescovitz","year":"2014","unstructured":"M.D. Pescovitz, C.J. Greenbaum, B. Bundy, D.J. Becker, S.E. Gitelman, R. Goland et al., B-Lymphocyte Depletion With Rituximab and \u03b2-Cell Function: Two-Year Results. Diabetes Care. 37(2), 453\u2013459 (2014). https:\/\/doi.org\/10.2337\/dc13-0626","journal-title":"Diabetes Care"},{"issue":"8","key":"4637_CR141","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1172\/JCI81722","volume":"125","author":"MR Rigby","year":"2015","unstructured":"M.R. Rigby, K.M. Harris, A. Pinckney, L.A. DiMeglio, M.S. Rendell, E.I. Felner et al., Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J. Clin. Invest. 125(8), 3285\u20133296 (2015). https:\/\/doi.org\/10.1172\/JCI81722","journal-title":"J. Clin. Invest."},{"issue":"10510","key":"4637_CR142","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(25)01674-5","volume":"406","author":"C Mathieu","year":"2025","unstructured":"C. Mathieu, J. Wych, A.E.J. Hendriks, Van L. Ryckeghem, T. Tree, P. Chmura et al., Minimum effective low dose of antithymocyte globulin in people aged 5\u201325 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. Lancet. 406(10510), 1375\u20131388 (2025). https:\/\/doi.org\/10.1016\/S0140-6736(25)01674-5","journal-title":"Lancet"},{"issue":"10519","key":"4637_CR143","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1016\/S0140-6736(25)01726-X","volume":"406","author":"AG Ziegler","year":"2025","unstructured":"A.G. Ziegler, P. Achenbach, A. Wei\u00df, R. Berner, K. Casteels, H. Elding Larsson et al., Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial. Lancet. 406(10519), 2564\u20132576 (2025). https:\/\/doi.org\/10.1016\/S0140-6736(25)01726-X","journal-title":"Lancet"},{"key":"4637_CR144","doi-asserted-by":"publisher","unstructured":"A.G. Ziegler, A. Albeer, S. Arnolds, R. Assfalg, M. Bunk, C. Daniel et al., Effect of High-Dose Oral Insulin in Children With Stage 1 Type 1 Diabetes: The Fr1da Insulin Intervention Randomized Controlled Trial. Diabetes Care. dc252818 (2026). https:\/\/doi.org\/10.2337\/dc25-2818","DOI":"10.2337\/dc25-2818"},{"issue":"1","key":"4637_CR145","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41467-022-28360-2","volume":"13","author":"F D\u2019Addio","year":"2022","unstructured":"F. D\u2019Addio, A. Maestroni, E. Assi, M. Ben Nasr, G. Amabile, V. Usuelli et al., The IGFBP3\/TMEM219 pathway regulates beta cell homeostasis. Nat. Commun. 13(1), 684 (2022). https:\/\/doi.org\/10.1038\/s41467-022-28360-2","journal-title":"Nat. Commun."},{"issue":"8","key":"4637_CR146","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41591-018-0089-4","volume":"24","author":"F Ovalle","year":"2018","unstructured":"F. Ovalle, T. Grimes, G. Xu, A.J. Patel, T.B. Grayson, L.A. Thielen et al., Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat. Med. 24(8), 1108\u20131112 (2018). https:\/\/doi.org\/10.1038\/s41591-018-0089-4","journal-title":"Nat. Med."},{"issue":"12","key":"4637_CR147","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2023.2064","volume":"329","author":"GP Forlenza","year":"2023","unstructured":"G.P. Forlenza, J. McVean, R.W. Beck, C. Bauza, R. Bailey, B. Buckingham et al., Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA 329(12), 990 (2023). https:\/\/doi.org\/10.1001\/jama.2023.2064","journal-title":"JAMA"},{"issue":"11","key":"4637_CR148","doi-asserted-by":"publisher","first-page":"e091597","DOI":"10.1136\/bmjopen-2024-091597","volume":"14","author":"J Wych","year":"2024","unstructured":"J. Wych, M. Brunner, R. Stenson, P.J. Chmura, T. Danne, A.P. Mander et al., Investigating the effect of verapamil on preservation of beta-cell function in adults with newly diagnosed type 1 diabetes mellitus (Ver-A-T1D): protocol for a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial. BMJ Open. 14(11), e091597 (2024). https:\/\/doi.org\/10.1136\/bmjopen-2024-091597","journal-title":"BMJ Open."},{"issue":"12","key":"4637_CR149","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00125-022-05780-9","volume":"65","author":"A Weiss","year":"2022","unstructured":"A. Weiss, J. Zapardiel-Gonzalo, F. Voss, M. Jolink, J. Stock, F. Haupt et al., Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia. 65(12), 2121\u20132131 (2022). https:\/\/doi.org\/10.1007\/s00125-022-05780-9","journal-title":"Diabetologia"},{"issue":"11","key":"4637_CR150","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1210\/clinem\/dgaf086","volume":"110","author":"A Galderisi","year":"2025","unstructured":"A. Galderisi, J. Bonet, H.M. Ismail, A. Moran, P. Fiorina, E. Bosi et al., Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of \u03b2 Cell Function. J. Clin. Endocrinol. Metabolism. 110(11), 3168\u20133178 (2025). https:\/\/doi.org\/10.1210\/clinem\/dgaf086","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"4637_CR151","doi-asserted-by":"publisher","unstructured":"M.A. Roma-Wilson, P. Pozzilli, Corrigendum to \u2018What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?\u2019 [JDC, Vol. 39, Issue 10, October 2025, 109132]. Journal of Diabetes and its Complications. 2026;40(3):109230. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109230","DOI":"10.1016\/j.jdiacomp.2025.109230"},{"issue":"6","key":"4637_CR152","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1007\/s00125-025-06394-7","volume":"68","author":"R Moulder","year":"2025","unstructured":"R. Moulder, M.K. Hirvonen, T. V\u00e4likangas, T. Suomi, L. Overbergh, M. Peakman et al., Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes affirms markers of disease. Diabetologia. 68(6), 1108\u20131114 (2025). https:\/\/doi.org\/10.1007\/s00125-025-06394-7","journal-title":"Diabetologia"},{"issue":"11","key":"4637_CR153","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s00125-023-05974-9","volume":"66","author":"R Moulder","year":"2023","unstructured":"R. Moulder, T. V\u00e4likangas, M.K. Hirvonen, T. Suomi, C.A. Brorsson, N. Lietz\u00e9n et al., Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory. Diabetologia. 66(11), 1983\u20131996 (2023). https:\/\/doi.org\/10.1007\/s00125-023-05974-9","journal-title":"Diabetologia"},{"key":"4637_CR154","doi-asserted-by":"publisher","first-page":"104625","DOI":"10.1016\/j.ebiom.2023.104625","volume":"92","author":"T Suomi","year":"2023","unstructured":"T. Suomi, I. Starskaia, U.U. Kalim, O. Rasool, M.K. Jaakkola, T. Gr\u00f6nroos et al., Gene expression signature predicts rate of type 1 diabetes progression. eBioMedicine. 92, 104625 (2023). https:\/\/doi.org\/10.1016\/j.ebiom.2023.104625","journal-title":"eBioMedicine"},{"issue":"2","key":"4637_CR155","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2337\/db16-0714","volume":"66","author":"T Viisanen","year":"2017","unstructured":"T. Viisanen, E.L. Ihantola, K. N\u00e4nt\u00f6-Salonen, H. Hy\u00f6ty, N. Nurminen, J. Selvenius et al., Circulating CXCR5\u2009+\u2009PD-1\u2009+\u2009ICOS+ Follicular T Helper Cells Are Increased Close to the Diagnosis of Type 1 Diabetes in Children With Multiple Autoantibodies. Diabetes. 66(2), 437\u2013447 (2017). https:\/\/doi.org\/10.2337\/db16-0714","journal-title":"Diabetes"},{"key":"4637_CR156","doi-asserted-by":"publisher","unstructured":"X. Xu, Y. Shi, Y. Cai, Q. Zhang, F. Yang, H. Chen et al., Inhibition of Increased Circulating Tfh Cell by Anti-CD20 Monoclonal Antibody in Patients with Type 1 Diabetes. Xu A, editor. PLoS ONE. 2013;8(11):e79858. https:\/\/doi.org\/10.1371\/journal.pone.0079858","DOI":"10.1371\/journal.pone.0079858"},{"issue":"18","key":"4637_CR157","doi-asserted-by":"publisher","first-page":"e177492","DOI":"10.1172\/JCI177492","volume":"134","author":"A Lled\u00f3-Delgado","year":"2024","unstructured":"A. Lled\u00f3-Delgado, P. Preston-Hurlburt, S. Currie, P. Clark, P.S. Linsley, S.A. Long et al., Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes. J. Clin. Invest. 134(18), e177492 (2024). https:\/\/doi.org\/10.1172\/JCI177492","journal-title":"J. Clin. Invest."},{"issue":"5","key":"4637_CR158","doi-asserted-by":"publisher","first-page":"eaai7793","DOI":"10.1126\/sciimmunol.aai7793","volume":"1","author":"SA Long","year":"2016","unstructured":"S.A. Long, J. Thorpe, H.A. DeBerg, V. Gersuk, J.A. Eddy, K.M. Harris et al., Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci. Immunol. 1(5), eaai7793 (2016). https:\/\/doi.org\/10.1126\/sciimmunol.aai7793","journal-title":"Sci. Immunol."},{"issue":"10","key":"4637_CR159","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.2337\/db14-0047","volume":"63","author":"T Orban","year":"2014","unstructured":"T. Orban, C.A. Beam, P. Xu, K. Moore, Q. Jiang, J. Deng et al., Reduction in CD4 Central Memory T-Cell Subset in Costimulation Modulator Abatacept-Treated Patients With Recent-Onset Type 1 Diabetes Is Associated With Slower C-Peptide Decline. Diabetes. 63(10), 3449\u20133457 (2014). https:\/\/doi.org\/10.2337\/db14-0047","journal-title":"Diabetes"},{"issue":"6","key":"4637_CR160","doi-asserted-by":"publisher","first-page":"e70074","DOI":"10.1002\/dmrr.70074","volume":"41","author":"ST Jerram","year":"2025","unstructured":"S.T. Jerram, J.H.M. Yang, E. Williams, C. Domingo-Vila, Y. Liu, M. Peakman et al., Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects. Diabetes Metabolism Res. 41(6), e70074 (2025). https:\/\/doi.org\/10.1002\/dmrr.70074","journal-title":"Diabetes Metabolism Res."},{"issue":"5","key":"4637_CR161","doi-asserted-by":"publisher","first-page":"e3833","DOI":"10.1002\/dmrr.3833","volume":"40","author":"JJA Armenteros","year":"2024","unstructured":"J.J.A. Armenteros, C. Brorsson, C.H. Johansen, K. Banasik, G. Mazzoni, R. Moulder et al., Multi-omics analysis reveals drivers of loss of \u03b2 \u2010cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter study. Diabetes Metabolism Res. 40(5), e3833 (2024). https:\/\/doi.org\/10.1002\/dmrr.3833","journal-title":"Diabetes Metabolism Res."},{"issue":"1","key":"4637_CR162","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13148-020-00906-5","volume":"12","author":"F Syed","year":"2020","unstructured":"F. Syed, S.A. Tersey, J.V. Turatsinze, J.L. Felton, N.J. Kang, J.B. Nelson et al., Circulating unmethylated CHTOP and INS DNA fragments provide evidence of possible islet cell death in youth with obesity and diabetes. Clin. Epigenet. 12(1), 116 (2020). https:\/\/doi.org\/10.1186\/s13148-020-00906-5","journal-title":"Clin. Epigenet"},{"issue":"3","key":"4637_CR163","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1210\/clinem\/dgaa008","volume":"105","author":"C Speake","year":"2020","unstructured":"C. Speake, A. Ylescupidez, D. Neiman, R. Shemer, B. Glaser, S.A. Tersey et al., Circulating Unmethylated Insulin DNA As a Biomarker of Human Beta Cell Death: A Multi-laboratory Assay Comparison. J. Clin. Endocrinol. Metabolism. 105(3), 781\u2013791 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgaa008","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"7014","key":"4637_CR164","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature03076","volume":"432","author":"MN Poy","year":"2004","unstructured":"M.N. Poy, L. Eliasson, J. Krutzfeldt, S. Kuwajima, X. Ma, P.E. MacDonald et al., A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 432(7014), 226\u2013230 (2004). https:\/\/doi.org\/10.1038\/nature03076","journal-title":"Nature"},{"issue":"10","key":"4637_CR165","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00109-015-1296-9","volume":"93","author":"M Latreille","year":"2015","unstructured":"M. Latreille, K. Herrmanns, N. Renwick, T. Tuschl, M.T. Malecki, M.I. McCarthy et al., miR-375 gene dosage in pancreatic \u03b2-cells: implications for regulation of \u03b2-cell mass and biomarker development. J. Mol. Med. 93(10), 1159\u20131169 (2015). https:\/\/doi.org\/10.1007\/s00109-015-1296-9","journal-title":"J. Mol. Med."},{"key":"4637_CR166","doi-asserted-by":"publisher","first-page":"103685","DOI":"10.1016\/j.eclinm.2025.103685","volume":"90","author":"L Piemonti","year":"2025","unstructured":"L. Piemonti, A.M. Bolla, A. Caretto, R. Melzi, A. Mercalli, V. Sordi et al., Induction of immune education in type 1 diabetes through controlled allogeneic islet rejection at onset: a monocentric open-label pilot study. eClinicalMedicine. 90, 103685 (2025). https:\/\/doi.org\/10.1016\/j.eclinm.2025.103685","journal-title":"eClinicalMedicine"},{"issue":"2","key":"4637_CR167","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00125-016-4156-4","volume":"60","author":"N Samandari","year":"2017","unstructured":"N. Samandari, A.H. Mirza, L.B. Nielsen, S. Kaur, P. Hougaard, S. Fredheim et al., Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1 diabetes mellitus. Diabetologia. 60(2), 354\u2013363 (2017). https:\/\/doi.org\/10.1007\/s00125-016-4156-4","journal-title":"Diabetologia"},{"issue":"6","key":"4637_CR168","doi-asserted-by":"publisher","first-page":"101591","DOI":"10.1016\/j.xcrm.2024.101591","volume":"5","author":"G Sebastiani","year":"2024","unstructured":"G. Sebastiani, G.E. Grieco, M. Bruttini, S. Auddino, A. Mori, M. Toniolli et al., A set of circulating microRNAs belonging to the 14q32 chromosome locus identifies two subgroups of individuals with recent-onset type 1 diabetes. Cell. Rep. Med. 5(6), 101591 (2024). https:\/\/doi.org\/10.1016\/j.xcrm.2024.101591","journal-title":"Cell. Rep. Med."},{"issue":"6","key":"4637_CR169","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00125-025-06397-4","volume":"68","author":"S Auddino","year":"2025","unstructured":"S. Auddino, E. Aiello, G.E. Grieco, D. Fignani, G. Licata, M. Bruttini et al., Comprehensive sequencing profile and functional analysis of IsomiRs in human pancreatic islets and beta cells. Diabetologia. 68(6), 1261\u20131278 (2025). https:\/\/doi.org\/10.1007\/s00125-025-06397-4","journal-title":"Diabetologia"},{"issue":"1","key":"4637_CR170","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00125-019-05026-1","volume":"63","author":"G Ventriglia","year":"2020","unstructured":"G. Ventriglia, F. Mancarella, G. Sebastiani, D.P. Cook, R. Mallone, C. Mathieu et al., miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes. Diabetologia. 63(1), 124\u2013136 (2020). https:\/\/doi.org\/10.1007\/s00125-019-05026-1","journal-title":"Diabetologia"},{"issue":"2","key":"4637_CR171","doi-asserted-by":"publisher","first-page":"103114","DOI":"10.1016\/j.arcmed.2024.103114","volume":"56","author":"AS Santos","year":"2025","unstructured":"A.S. Santos, D.P. Santos-Bezerra, L.R.P. Ferreira, S.Y. Bando, L.I. Alves, E. Cunha-Neto et al., Relevance of Circulating microRNA, and their Association with Islet Cell Autoantibodies in Type 1 Diabetes Pathogenesis. Arch. Med. Res. 56(2), 103114 (2025). https:\/\/doi.org\/10.1016\/j.arcmed.2024.103114","journal-title":"Arch. Med. Res."},{"issue":"6","key":"4637_CR172","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/17410541.2025.2563498","volume":"22","author":"GE Grieco","year":"2025","unstructured":"G.E. Grieco, F. Dotta, G. Sebastiani, Leveraging circulating microRNAs for personalized disease-modifying therapies in type 1 diabetes. Personalized Med. 22(6), 481\u2013493 (2025). https:\/\/doi.org\/10.1080\/17410541.2025.2563498","journal-title":"Personalized Med."},{"issue":"10","key":"4637_CR173","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2337\/db22-0852","volume":"72","author":"G Sassi","year":"2023","unstructured":"G. Sassi, G. Licata, G. Ventriglia, A. Wouters, P. Lemaitre, R. Seurinck et al., A Plasma miR-193b-365 Signature Combined With Age and Glycemic Status Predicts Response to Lactococcus lactis \u2013Based Antigen-Specific Immunotherapy in New-Onset Type 1 Diabetes. Diabetes. 72(10), 1470\u20131482 (2023). https:\/\/doi.org\/10.2337\/db22-0852","journal-title":"Diabetes"},{"issue":"2","key":"4637_CR174","doi-asserted-by":"publisher","first-page":"448","DOI":"10.2337\/db15-1625","volume":"66","author":"T Takiishi","year":"2017","unstructured":"T. Takiishi, D.P. Cook, H. Korf, G. Sebastiani, F. Mancarella, J.P.M.C.M. Cunha et al., Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10\u2013Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. Diabetes. 66(2), 448\u2013459 (2017). https:\/\/doi.org\/10.2337\/db15-1625","journal-title":"Diabetes"},{"issue":"1","key":"4637_CR175","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00125-023-06014-2","volume":"67","author":"C Mathieu","year":"2024","unstructured":"C. Mathieu, A. Wiedeman, K. Cerosaletti, S.A. Long, E. Serti, L. Cooney et al., A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab. Diabetologia. 67(1), 27\u201341 (2024). https:\/\/doi.org\/10.1007\/s00125-023-06014-2","journal-title":"Diabetologia"},{"issue":"8","key":"4637_CR176","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","volume":"9","author":"SE Gitelman","year":"2021","unstructured":"S.E. Gitelman, B.N. Bundy, E. Ferrannini, N. Lim, J.L. Blanchfield, L.A. DiMeglio et al., Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 9(8), 502\u2013514 (2021). https:\/\/doi.org\/10.1016\/S2213-8587(21)00139-X","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"4637_CR177","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1038\/s41591-025-03730-7","volume":"31","author":"MV Joglekar","year":"2025","unstructured":"M.V. Joglekar, W.K.M. Wong, P.S. Kunte, H.P. Hardikar, R.A. Kulkarni, I. Ahmed et al., A microRNA-based dynamic risk score for type 1 diabetes. Nat. Med. 31(8), 2622\u20132631 (2025). https:\/\/doi.org\/10.1038\/s41591-025-03730-7","journal-title":"Nat. Med."},{"issue":"3","key":"4637_CR178","doi-asserted-by":"publisher","first-page":"100606","DOI":"10.1016\/j.xpro.2021.100606","volume":"2","author":"GE Grieco","year":"2021","unstructured":"G.E. Grieco, G. Sebastiani, D. Fignani, N. Brusco, L. Nigi, C. Formichi et al., Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples. STAR. Protocols. 2(3), 100606 (2021). https:\/\/doi.org\/10.1016\/j.xpro.2021.100606","journal-title":"STAR. Protocols"},{"issue":"11","key":"4637_CR179","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00125-022-05778-3","volume":"65","author":"ALJ Carr","year":"2022","unstructured":"A.L.J. Carr, C. Evans-Molina, R.A. Oram, Precision medicine in type 1 diabetes. Diabetologia. 65(11), 1854\u20131866 (2022). https:\/\/doi.org\/10.1007\/s00125-022-05778-3","journal-title":"Diabetologia"},{"issue":"4","key":"4637_CR180","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2337\/dbi20-0054","volume":"71","author":"EK Sims","year":"2022","unstructured":"E.K. Sims, R.E.J. Besser, C. Dayan, C. Geno Rasmussen, C. Greenbaum, K.J. Griffin et al., Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 71(4), 610\u2013623 (2022). https:\/\/doi.org\/10.2337\/dbi20-0054","journal-title":"Diabetes"},{"issue":"S6","key":"4637_CR181","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/dom.16354","volume":"27","author":"E Bonifacio","year":"2025","unstructured":"E. Bonifacio, A. Ziegler, Type 1 diabetes risk factors, risk prediction and presymptomatic detection: Evidence and guidance for screening. Diabetes Obes. Metabolism. 27(S6), 28\u201339 (2025). https:\/\/doi.org\/10.1111\/dom.16354","journal-title":"Diabetes Obes. Metabolism"},{"issue":"6","key":"4637_CR182","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000543035","volume":"97","author":"MJ Haller","year":"2024","unstructured":"M.J. Haller, K.J. Bell, R.E.J. Besser, K. Casteels, J.J. Couper, M.E. Craig et al., ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes. Horm. Res. Paediatr. 97(6), 529\u2013545 (2024). https:\/\/doi.org\/10.1159\/000543035","journal-title":"Horm. Res. Paediatr."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04637-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:34:39Z","timestamp":1777876479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04637-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":182,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4637"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04637-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"167"}}